Back

Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Drug interactions, efficacy, and safety Cardiotoxicity of Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Jong-Hwan Joseph Lee

Toronto (Canada)

7 More presentations in this session

Presentation thumbnail
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
Ms A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device
Doctor K. Murata (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Drug-drug interactions of empagliflozin and dapagliflozin
Professor C. Stoellberger (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study
Mr S. Nielsen (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Drug interactions, efficacy, and safety

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study
thumbnail
Congress Presentation
Chalcone-enriched fraction protects against chemotherapy-induced cardiotoxicity by restoring mitochondrial function and reducing oxidative stress
thumbnail
Congress Presentation
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources